Suzanne Lentzsch, MD, PhD

This October, don’t miss: 'Advances in AL Amyloidosis: Biomarkers, Complications & Emerging Therapies' — a virtual CME program with video access and
4.0 ACCME credits. Friday, October 30, 2026. Diagnosis, transplantation & cell therapy. Register: buff.ly/orLJ7S0
#Amyloidosis #Hematology @rajshekharucms @MSHughes_MD

A milestone for κ-AL!! Japan approved anselamimab on Sept 16, following Ph III data showing a 62% reduction in mortality κ pt. We hope @FDA and @EMA_News will follow. Patients with rare, life-threatening diseases deserve hope and access to lifesaving treatment #amyloidosis @Amyloidosis_ASB @Amyloidosisfdn @Amyloid_Planet @AmyloidosisSupp @Amyloidosis_ARC

Happy July 4th!

One of the most rewarding and emotional moments of my career took place at #ASCO2026. In 2015, I started the first-in-human trial of 11-1F4 (now anselamimab), supported by a small FDA grant and @columbiacancer. At the time, the path forward was far from certain. We faced limited funding, strong competition from Prothena’s NEOD001 program, and considerable skepticism from industry given the rarity of AL amyloidosis and the fact that competing programs were already much further advanced in development.

Despite these challenges, we continued to move forward step by step. The phase 1 study demonstrated encouraging results, ultimately leading to the founding and funding of Caelum Biosciences in 2017 and the launch of the subsequent phase 2 and phase 3 studies. Those efforts were later advanced and completed through the commitment and resources of @AlexionCARES and @AstraZenecaUS.

@ASCO I had the privilege of chairing the session when the final phase 3 results where presented by Dr. Wechalekar, which demonstrated a significant overall survival benefit in patients with stage IIIA/IIIB κ AL amyloidosis🙌. Seeing a scientific concept evolve from an investigator-initiated first-in-human study into a positive phase 3 trial is extraordinarily rewarding.

This achievement reflects the dedication of countless patients, supporters🙏@MorieGertz, investigators, research staff, industry partners, and advocates who believed in this program over many years. It is also a powerful reminder of why we do translational research-to transform promising science into therapies that meaningfully improve patients' lives.

#ASCO2026 #ALAmyloidosis @Amyloidosis_ARC @Amyloidosisfdn @AmyloidosisSupp @ISA_Amyloidosis

#ASH25 Another presentation by @rajshekharucms in the same session on our Venetoclax investigator initiated trial in t11;14 RRAL Amyloidosis @rajshekharucms @vsanchorawala @columbiacancer